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In this issue of the Journal, Natale et al . (I) present their
findings in 91 patients with previous sudden cardiac death or
ventricular tachycardia refractory to antiarrhylhmic medica-
tions . The patients were assigned to two groups on the basis
of device availability . The experimental group of 36 patients
received a hybrid combination system consisting of the
Ventritex Cadence pulse generator (selected for its biphasic
waveform) and the Cardiac Pacemakers Inc. (CPI) Endotak
nonthoracotomy lead system . Although the Cadence pulse
generator and the Endotak lead system have been approved
individually by the Food and Drug Administration (FDA),
the performance of the two in combination has not been
evaluated by the agency .
The FDA commends the authors for their acknowledg-
ment that the Cadence/Endotak combination is not FDA
approved. The FDA has been concerned about the use of hy-
brid combinations of implantable cardioverter-defibrillators
and leads . For example, off-label use of the Endotak lead
system with implantable cardioverter-defibrillators iiii un-
evaluated combinations has been reported to result in the
failure to redetect ventricular fibrillation if the initial shock
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is unsuccessful in terminating the arrhythmia (2) . Although
the FDA is not aware of such reports for the Cadence and
Endozak combination, a clinical trial using this combination
would be incomplete without an evaluation of this possibility
.
If the combination of a biphasic waveform and a nontho-
racotomy lead system is truly beneficial, the public health
would obviously be best served by early availability of such
combinations . However, widespread adoption of such com-
binations is inappropriate without adequate data being avail-
able to guide practitioners and patients . Such data should he
submitted to and reviewed by the FDA . The FDA is the
principal agency charged by Congress to evaluate such data
as part of its role in the oversight of medical devices
marketing and promotion .
To make product evaluations meaningful, it is best if
researchers share their insight and expertise and combine
institutional experience in a joint study . Single-center stud-
ies are usually too small to allow adequate device evaluation .
Multicenter studies or a meta-analysis of many similar small
studies, if combined, may provide enough information for
the FDA to more quickly decide about a device's safety and
effectiveness .
Viewed in this light, Natale et al . might have provided a
greater service to the medical community if they had worked
with the manufacturers under their Investigational Device
Exemption (IDE) in evaluating this combination . Alterna-
tively, the authors could have applied for an independent
IDE to study this combination. Their data could then have
been evaluated by the FDA in conjunction with data submit-
ted by the industry . This would most likely increase the
speed of the accumulation of the clinical data necessary to
support the FDA's evaluation and proper labeling of the
Ventritex Cadence and CPI Endotak lead system combina-
tion .
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